HCM
TRIB

Highbridge Capital Management’s Trinity Biotech TRIB Stock Holding History

Highbridge Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-230,322
Closed -$1.22M – 721
2022
Q1 		$1.22M Buy
+230,322
New +$1.33M 0.03% 346

Other funds holding TRIB

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

Highbridge Capital Management's TRIB Position: Q2 2022 in Review

Highbridge Capital Management sold out of Trinity Biotech (TRIB) in Q2 2022, closing a stake of 230,322 shares — an estimated $1.22M sold.

Highbridge Capital Management first reported a position in TRIB in Q1 2022 and held it in 1 quarter. The position peaked at $1.22M in Q1 2022. 20 funds tracked by Wall St. Rank hold TRIB as of Q2 2022.

  • Highbridge Capital Management reported no remaining Trinity Biotech position as of Q2 2022 after selling out during the quarter.
  • Highbridge Capital Management sold 230,322 Trinity Biotech shares in Q2 2022, an estimated $1.22M.
  • Highbridge Capital Management first reported a position in Trinity Biotech in Q1 2022 and held it in 1 quarter.
  • Highbridge Capital Management's Trinity Biotech position peaked at $1.22M in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2022.

Based on Highbridge Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.